Neurotech International (ASX:NTI) said the 28-day good laboratory practice oral toxicology studies in rats and dogs evaluating its NTI164 drug candidate demonstrated excellent tolerability and no safety concerns, according to a Monday Australian bourse filing.
The animals received twice-daily oral dosing across low, mid, and high dose levels, followed by a 14-day recovery period.
It said that no test article-related adverse effects were observed across clinical observations, ophthalmic exams, neurological assessments, or clinical pathology.
The firm is focused on treating paediatric neurological disorders via the NTI164 broad-spectrum oral cannabinoid drug therapy candidate.
Its shares rose 9% on Monday's close.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。